Europe’s first participants to take part in ATLAS were recently recruited at NIHR National Patient Recruitment Centre (NPRC) based in Bradford.
Europe’s first participants to take part in the ATLAS trial were recently recruited at NIHR National Patient Recruitment Centre (NPRC) based in Bradford.
Sanofi-Aventis Recherche & Développement, launched the phase 3 clinical trial of Dupilumab, in the UK on Thursday 9 June 2022. The first participants enrolled at NIHR PRC in Bradford on Thursday 09 June 2022, the day it opened to recruitment.
The study will investigate the effectiveness, safety and tolerability of a new treatment called Dupilumab, which is administered as an injection. The study will assess the long-term effect of dupilumab on prevention of lung function decline in adult patients with uncontrolled moderate to severe Asthma.
Professor Dinesh Saralaya, Consultant Respiratory Physician & Director of the NIHR PRC, Bradford and Principal Investigator on the ATLAS clinical trial, said:
“Bradford has recruited a European-first, adding to our extensive track record of recruitment successes including previous Global first and European first recruits. It is further evidence of our expertise and capabilities here in Bradford and we look forward to continuing this success with our extensive portfolio of commercial studies. It's also a testament to the hard work of our team and the commitment of our patients to research and improving care”
The study will take place at the PRC: Bradford’s state-of-the-art facilities based at Bradford NHS Trust. The national Patient Recruitment Centres (PRCs) are the first family of NIHR-funded research facilities that are 100% dedicated to delivering commercial research. They are purpose-designed to increase the UK’s capacity to deliver large scale, late-phase commercial clinical trials and to make it easier and quicker to deliver commercial research in our NHS and wider care settings.
This European-first patient is further evidence to the service the PRC’s are providing commercial partners and patients.
Being the first country to recruit a patient in a global trial is a key performance indicator for the life sciences industry as it shows that the UK can support the rapid set-up and recruitment of studies.
